Literature DB >> 25740311

Microtubule association of EML proteins and the EML4-ALK variant 3 oncoprotein require an N-terminal trimerization domain.

Mark W Richards1, Laura O'Regan1, Daniel Roth2, Jessica M Montgomery1, Anne Straube2, Andrew M Fry1, Richard Bayliss1.   

Abstract

Proteins of the echinoderm microtubule (MT)-associated protein (EMAP)-like (EML) family contribute to formation of the mitotic spindle and interphase MT network. EML1-4 consist of Trp-Asp 40 (WD40) repeats and an N-terminal region containing a putative coiled-coil. Recurrent gene rearrangements in non-small cell lung cancer (NSCLC) fuse EML4 to anaplastic lymphoma kinase (ALK) causing expression of several oncogenic fusion variants. The fusions have constitutive ALK activity due to self-association through the EML4 coiled-coil. We have determined crystal structures of the coiled-coils from EML2 and EML4, which describe the structural basis of both EML self-association and oncogenic EML4-ALK activation. The structures reveal a trimeric oligomerization state directed by a conserved pattern of hydrophobic residues and salt bridges. We show that the trimerization domain (TD) of EML1 is necessary and sufficient for self-association. The TD is also essential for MT binding; however, this property requires an adjacent basic region. These observations prompted us to investigate MT association of EML4-ALK and EML1-ABL1 (Abelson 1) fusions in which variable portions of the EML component are present. Uniquely, EML4-ALK variant 3, which includes the TD and basic region of EML4 but none of the WD40 repeats, was localized to MTs, both when expressed recombinantly and when expressed in a patient-derived NSCLC cell line (H2228). This raises the question of whether the mislocalization of ALK activity to MTs might influence downstream signalling and malignant properties of cells. Furthermore, the structure of EML4 TD may enable the development of protein-protein interaction inhibitors targeting the trimerization interface, providing a possible avenue towards therapeutic intervention in EML4-ALK NSCLC.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25740311     DOI: 10.1042/BJ20150039

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  25 in total

1.  Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).

Authors:  Chengwei Zhang; Xiao-Ran Han; Xiaobao Yang; Biao Jiang; Jing Liu; Yue Xiong; Jian Jin
Journal:  Eur J Med Chem       Date:  2018-03-27       Impact factor: 6.514

2.  Complete Pathological Response to Crizotinib in a Patient with ALK-rearranged Lung Adenocarcinoma.

Authors:  Marissa S Mattar; Jason Chang; Ryma Benayed; Darragh Halpenny; Astin Powers; David E Kleiner; Alexander Drilon; Mark G Kris
Journal:  Clin Lung Cancer       Date:  2019-10-13       Impact factor: 4.785

Review 3.  Canadian perspectives: update on inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.

Authors:  B Melosky; P Cheema; J Agulnik; R Albadine; D G Bebb; N Blais; R Burkes; C Butts; P B Card; A M Y Chan; V Hirsh; D N Ionescu; R Juergens; W Morzycki; Z Poonja; R Sangha; M Tehfe; M S Tsao; M Vincent; Z Xu; G Liu
Journal:  Curr Oncol       Date:  2018-10-31       Impact factor: 3.677

4.  Novel TENM3-ALK fusion is an alternate mechanism for ALK activation in neuroblastoma.

Authors:  Mitsuteru Hiwatari; Masafumi Seki; Ryosuke Matsuno; Kenichi Yoshida; Takeshi Nagasawa; Aiko Sato-Otsubo; Shohei Yamamoto; Motohiro Kato; Kentaro Watanabe; Masahiro Sekiguchi; Satoru Miyano; Seishi Ogawa; Junko Takita
Journal:  Oncogene       Date:  2022-04-11       Impact factor: 9.867

5.  EML2-S constitutes a new class of proteins that recognizes and regulates the dynamics of tyrosinated microtubules.

Authors:  Takashi Hotta; Thomas S McAlear; Yang Yue; Takumi Higaki; Sarah E Haynes; Alexey I Nesvizhskii; David Sept; Kristen J Verhey; Susanne Bechstedt; Ryoma Ohi
Journal:  Curr Biol       Date:  2022-08-12       Impact factor: 10.900

Review 6.  Ectopic biomolecular phase transitions: fusion proteins in cancer pathologies.

Authors:  Richoo B Davis; Mahdi Muhammad Moosa; Priya R Banerjee
Journal:  Trends Cell Biol       Date:  2022-04-25       Impact factor: 21.167

7.  ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties.

Authors:  Merrida A Childress; Stephen M Himmelberg; Huiqin Chen; Wanleng Deng; Michael A Davies; Christine M Lovly
Journal:  Mol Cancer Res       Date:  2018-07-12       Impact factor: 5.852

8.  In vivo Engineering of Chromosome 19 q-arm by Employing the CRISPR/AsCpf1 and ddAsCpf1 Systems in Human Malignant Gliomas (Hypothesis).

Authors:  Atefe Abak; Hamed Shoorei; Mohammad Taheri; Soudeh Ghafouri-Fard
Journal:  J Mol Neurosci       Date:  2021-05-15       Impact factor: 3.444

9.  Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules.

Authors:  Asmin Tulpule; Juan Guan; Dana S Neel; Hannah R Allegakoen; Yone Phar Lin; David Brown; Yu-Ting Chou; Ann Heslin; Nilanjana Chatterjee; Shriya Perati; Shruti Menon; Tan A Nguyen; Jayanta Debnath; Alejandro D Ramirez; Xiaoyu Shi; Bin Yang; Siyu Feng; Suraj Makhija; Bo Huang; Trever G Bivona
Journal:  Cell       Date:  2021-04-12       Impact factor: 41.582

10.  EML4-ALK V3 oncogenic fusion proteins promote microtubule stabilization and accelerated migration through NEK9 and NEK7.

Authors:  Laura O'Regan; Giancarlo Barone; Rozita Adib; Chang Gok Woo; Hui Jeong Jeong; Emily L Richardson; Mark W Richards; Patricia A J Muller; Spencer J Collis; Dean A Fennell; Jene Choi; Richard Bayliss; Andrew M Fry
Journal:  J Cell Sci       Date:  2020-05-11       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.